Research

Zacks Small Cap Research – ORMP: Preparations for New Phase 3 Trial Advance, While ORMP Leverages Balance Sheet Through Recent Agreements – Go Health Pro

by
Zacks Small Cap Research – ORMP: Preparations for New Phase 3 Trial Advance, While ORMP Leverages Balance Sheet Through Recent Agreements – Go Health Pro

By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Planning Phase 3 Oral Insulin study under revised protocol, new CRO agreement in place Oramed Pharmaceuticals (NASDAQ:ORMP) has pivoted its clinical R&D focus to prioritize studying ORMD 0801 for subpopulations of patients with pooled specific parameters who responded well to oral insulin in its prior … Read more

ABI Research Forecasts Strong Demand For Biometric Hardware – Go Health Pro

by
ABI Research Forecasts Strong Demand For Biometric Hardware – Go Health Pro

ABI Research’s Biometrics Technologies and Applications market data report forecasts revenues for biometric hardware devices are set to reach US$9 billion worldwide by 2027. The report noted that alongside strong growth in biometric devices, rising in revenue from US$7 billion in 2022, consumer electronics (smartphone, tablet, wearable) biometric capability will markedly increase in future years. … Read more

Zacks Small Cap Research – NRXBF: Promising Company Releases Results – Go Health Pro

by

By Brad Sorensen, CFA OTC:NRXBF READ THE FULL NRXBF RESEARCH REPORT NurExone (OTC:NRXBF) is developing a product known as ExoPTEN that is designed to treat patients with acute spinal cord injuries and these numbers suggest a potential market for ExoPTEN of approximately 50,000 new cases globally per year—an enormous market potential with patients eager to … Read more

Zacks Small Cap Research – QSG: F1Q25 Earnings Review: EPS Miss on Lower Revenues; Silver Transition Gaining Momentum – Go Health Pro

by

By Michael Kim NASDAQ:QSG READ THE FULL QSG RESEARCH REPORT Pre-market open on 11/27/24, QuantaSing (NASDAQ:QSG) reported F1Q25 (Sep) earnings results. On a GAAP basis, QSG reported net income of $11.5 million for F1Q25, or $0.21 per ADS. That said, excluding share-based compensation expenses, adjusted EPS came in at $0.23, or below our estimate of … Read more

Zacks Small Cap Research – IMNN: Comes to Alignment with FDA Regarding Phase 3 Protocol for IMNN-001… – Go Health Pro

by

By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Reaches Alignment with FDA Regarding Phase 3 Trial Plan On November 25, 2024, Imunon, Inc. (NASDAQ:IMNN) announced it had reached alignment with the U.S. Food and Drug Administration (FDA) following an ‘End-of-Phase 2’ meeting on the company’s proposed plan for a Phase … Read more

x